Half of Kids with Inflammatory Syndrome After COVID-19 Have Neurologic Symptoms apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
Black People May Respond Differently to Common MS Therapy Than White People
Black people who have autoimmune neurologic diseases, multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD), may respond differently than white people to a common therapy meant to modulate the immune system, according to researchers.
The people in this study were given anti-CD20 infusion therapies, which are often used to treat autoimmune diseases such as MS and neuromyelitis optica spectrum disorder, which is a relapsing inflammatory disorder of the optic nerve, spinal cord and brain. The goal of this treatment, called B-cell depletion therapy, is to destroy B-cells in blood circulation. B-cells are partly responsible for the abnormal autoimmune responses in people with MS and NMOSD, a media release from the American Academy of Neurology explains.
Stroke occurs infrequently in large cohort study of patients hospitalized with COVID-19 Source:
Fanning J, et al. Stroke complicating critically ill patients with SARS-CoV-2: Analysis of the COVID-19 Critical Care Consortium (CCCC) international, multicenter observational study. Presented at: American Academy of Neurology Annual Meeting; April 17-22, 2021 (virtual meeting). Disclosures: Healio Neurology could not confirm relevant financial disclosures at the time of publication. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Subscribe ADDED TO EMAIL ALERTS
You ve successfully added to your alerts. You will receive an email when new content is published.
New data for Roche’s OCREVUS (ocrelizumab) reinforce significant benefit on slowing disease progression in relapsing and primary progressive multiple sclerosis F. Hoffmann-La Roche Ltd Basel, SWITZERLAND
85% of treatment-naïve, early-stage relapsing-remitting multiple sclerosis (RRMS) patients achieved no evidence of disease activity (NEDA) in open-label Phase IIIb ENSEMBLE study
OCREVUS significantly slowed loss of brain tissue within T2 MRI lesions in primary progressive multiple sclerosis (PPMS) in post-hoc analysis of Phase III ORATORIO study
OCREVUS-treated patients show highest adherence and persistence rates compared with other disease-modifying therapies (DMTs) in two-year U.S. claims analysis
Basel, 16 April 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new OCREVUS® (ocrelizumab) analyses supporting its significant benefit on disease progression in early-stage relapsing-remitting multiple sclerosis (RRMS) and primary progressi
Message :
Required fields 85% of treatment-naïve, early-stage relapsing-remitting multiple sclerosis (RRMS) patients achieved no evidence of disease activity (NEDA) in open-label Phase IIIb ENSEMBLE study OCREVUS significantly slowed loss of brain tissue within T2 MRI lesions in primary progressive multiple sclerosis (PPMS) in post-hoc analysis of Phase III ORATORIO study OCREVUS-treated patients show highest adherence and persistence rates compared with other disease-modifying therapies (DMTs) in two-year U.S. claims analysis Basel, 16 April 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today
announced new OCREVUS(R) (ocrelizumab) analyses supporting its
significant benefit on disease progression in early-stage
relapsing-remitting multiple sclerosis (RRMS) and primary progressive MS